Here's Our Take On The Global Blood Therapeutics Inc (GBT) Rumors
Global Blood Therapeutics Inc (NASDAQ:GBT) is spiking towards the end of the week on the suggestion that it might be an acquisition target for a big pharma name.
Global Blood Therapeutics Inc. (GBT)
Market is closed
News
- First
- << Previous
- 21 - 28
Is Global Blood Therapeutics Inc (GBT) A Good Stock To Buy?
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals.
Here's Why Global Blood, Deutsche Bank, PayPal, and Two Other Stocks Are Trending Today
Amid another spate of earnings releases all three main stock indexes are trading lower today. The Dow Jones is down by 0.21%, the S&P 500 is 0.30% in the red, and the NASDAQ index is close has lost ...
5 Stocks That Healthcare Fund Deerfield Management Was Buying in Q2
Founded by James E. Flynn in 2000, Deerfield Management has grown to become one of the premier healthcare-focused investment management companies today.
Movers and Shakers in Biotech: Global Blood Therapeutics Inc (GBT) and Eleven Biotherapeutics Inc (EBIO)
It’s the start of a new week in biotech, and a number of potential catalysts promise to inject some volatility into the space going forward.
Here’s What To Watch From Global Blood Therapeutics Inc (GBT)
Global Blood Therapeutics Inc (NASDAQ:GBT) just kicked off a phase IIa trial in its lead sickle cell candidate, GBT440.
Market Defying Stocks: Why Axiall, Connecture, and 3 Other Stocks Are Rising on a Red Day
It's been a volatile day on Wall Street as the markets initially sold off sharply on fears of the consequences of a potential Brexit.
Deerfield Management Discloses 3.66% Stake In Newly Public Company Global Blood Therapeutics Inc. (GBT)
James E. Flynn’s Deerfield Management has filed a Schedule 13G disclosing a 3.66% ownership stake in the newly public company Global Blood Therapeutics Inc.
- First
- << Previous
- 21 - 28
Billionaire Hedge Funds
